A Study comparing Savolitinib plus Osimertinib vs Savolitinib plus Placebo in Patients with EGFRm+ and MET Amplified Advanced NSCLC - CoC

Study identifier:D5084C00009

ClinicalTrials.gov identifier:NCT04606771

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination with Osimertinib vs Savolitinib in Combination with Placebo in Patients with EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Osimertinib + Savolitinib, Savolitinib + Placebo

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 28 Sept 2020
Primary Completion Date: 21 Dec 2022
Estimated Study Completion Date: 20 Dec 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria